FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* White Mark Andrew (Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC.				RC 3. 0	2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. [RCKT] 3. Date of Earliest Transaction (Month/Day/Year) 04/04/2023							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer							
	RBROOK I	DRIVE	08512		4. 1	f Ame	ndment, I	Date (of Original	Filed	(Month/Da	ay/Year)		6. Ind Line)	Form fi	led by One led by More	Repo	(Check App rting Person One Report	.
(City)		tate)	(Zip)		Ri	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									to				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I			2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an			5. Amour Securitie Beneficia Owned F Reported	es Formally (D) (Sollowing (I) (I)		: Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount	ount (A) or (D)		rice	Transaction(s) (Instr. 3 and 4)				
Common Stock, par value \$0.01			04/04	1/2023			A		76,662	2(1) A		\$ <mark>0</mark>	76,6	,662(1)		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, Tra urity or Exercise (Month/Day/Year) if any Co		ransa ode (l	ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		[3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				c	ode	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amo or Num of Shar	nber					
Stock Option (Right to Buy)	\$17.41	04/04/2023			A		57,739		(2)	0	4/04/2033	Common Stock	57,7	739	\$0	57,739		D	

Explanation of Responses:

- 1. Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
- 2. This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

/s/ Martin Wilson, as attorneyin-fact for Mark Andrew White

04/12/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.